Einzeltreffer — DigiBib

Erenumab is a fully human anti-canonical calcitonin gene-related peptide receptor monoclonal antibody approved for migraine prevention. The Migraine-Specific Quality-of-Life Questionnaire (MSQ) is a 14-item patient-reported outcome instrument that measures the impact of migraine on health-related quality of life. Erenumab data from four phase II/III clinical trials were used to develop an item response theory (IRT) model within a nonlinear mixed effects framework, (i) evaluate the MSQ item information with respect to patient disability, (ii) characterize the longitudinal progression of the MSQ, and (iii) quantify the effect of erenumab on the MSQ in patients with migraine. The majority (80%) of information was found to be contained in 9 out of 14 items, extending the current knowledge on the reliability of the MSQ as a psychometric tool. Simulations across three MSQ domains show significant improvement from baseline, exceeding minimally important differences. Overall, the IRT model platform developed herein allows for systematic quantification of the effect of erenumab on the MSQ in patients with migraine.

Titel:	Evaluation of the effect of erenumab on migraine-specific questionnaire in patients with chronic and episodic migraine.
Autor/in / Beteiligte Person:	Chen, PW ; Karlsson, MO ; Ueckert, S ; Pritchard-Bell, A ; Hsu, CP ; Dutta, S ; Ahamadi, M
Link:	Full Text Finder (Volltext)
Zeitschrift:	CPT: pharmacometrics & systems pharmacology, Jg. 12 (2023-12-01), Heft 12, S. 1988-2000
Veröffentlichung:	2015- : Hoboken, NJ : Wiley ; <i>Original Publication</i>: New York, NY : Nature Pub. Group, 2023
Medientyp:	academicJournal
ISSN:	2163-8306 (electronic)
DOI:	10.1002/psp4.13048
Schlagwort:	Humans Reproducibility of Results Surveys and Questionnaires Quality of Life Migraine Disorders drug therapy Migraine Disorders prevention & control
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Journal Article; Research Support, Non-U.S. Gov't Language: English [CPT Pharmacometrics Syst Pharmacol] 2023 Dec; Vol. 12 (12), pp. 1988-2000. <i>Date of Electronic Publication: </i>2023 Oct 11. MeSH Terms: Quality of Life* ; Migraine Disorders* / drug therapy ; Migraine Disorders* / prevention & control ; Humans ; Reproducibility of Results ; Surveys and Questionnaires References: Headache. 2019 Sep;59(8):1253-1269. (PMID: 31168803) ; Qual Life Res. 2007 Sep;16(7):1231-7. (PMID: 17468941) ; Cephalalgia. 2009 Nov;29(11):1180-7. (PMID: 19830883) ; Comput Methods Programs Biomed. 2005 Sep;79(3):241-57. (PMID: 16023764) ; N Engl J Med. 2017 Nov 30;377(22):2123-2132. (PMID: 29171821) ; Comput Methods Programs Biomed. 1999 Jan;58(1):51-64. (PMID: 10195646) ; Health Qual Life Outcomes. 2019 Jun 24;17(1):108. (PMID: 31234894) ; J Pharmacokinet Pharmacodyn. 2019 Jun;46(3):273-285. (PMID: 31020450) ; Cephalalgia. 2013 Apr;33(5):289-90. (PMID: 23307815) ; Lancet Neurol. 2017 Jun;16(6):425-434. (PMID: 28460892) ; J Pharmacokinet Pharmacodyn. 2020 Oct;47(5):461-471. (PMID: 32617833) ; Comput Methods Programs Biomed. 2004 Aug;75(2):85-94. (PMID: 15212851) ; Headache. 2012 Mar;52(3):409-21. (PMID: 21929662) ; AAPS J. 2021 Mar 16;23(3):45. (PMID: 33728519) ; Pharm Res. 1998 Sep;15(9):1463-8. (PMID: 9755901) ; Curr Pain Headache Rep. 2012 Feb;16(1):86-92. (PMID: 22083262) ; Value Health. 2012 May;15(3):485-94. (PMID: 22583459) ; Headache. 1998 Apr;38(4):295-302. (PMID: 9595870) ; Headache. 2017 Oct;57(9):1385-1398. (PMID: 28857154) ; CPT Pharmacometrics Syst Pharmacol. 2023 Dec;12(12):1988-2000. (PMID: 37723849) ; Headache. 2000 Mar;40(3):204-15. (PMID: 10759923) ; Lancet Neurol. 2016 Apr;15(4):382-90. (PMID: 26879279) ; Med Care. 2000 Sep;38(9 Suppl):II28-42. (PMID: 10982088) ; Qual Life Res. 2003 Dec;12(8):887-902. (PMID: 14651410) ; Headache. 2012 Nov-Dec;52(10):1456-70. (PMID: 22830411) ; CPT Pharmacometrics Syst Pharmacol. 2018 Apr;7(4):205-218. (PMID: 29493119) ; Front Neurol. 2021 Jul 29;12:687697. (PMID: 34393974) ; J Neurol Neurosurg Psychiatry. 2022 Mar;93(3):254-262. (PMID: 34845002) ; Neurology. 2019 May 7;92(19):e2250-e2260. (PMID: 30996060) ; Cephalalgia. 2018 Sep;38(10):1622-1631. (PMID: 30086681) ; Eur J Neurol. 2021 May;28(5):1716-1725. (PMID: 33400330) ; Pharm Res. 2014 Aug;31(8):2152-65. (PMID: 24595495) ; J Headache Pain. 2020 Jun 9;21(1):69. (PMID: 32517693) ; Cephalalgia. 2018 May;38(6):1026-1037. (PMID: 29471679) Grant Information: AMGEN Inc. Substance Nomenclature: I5I8VB78VT (erenumab) Entry Date(s): Date Created: 20230919 Date Completed: 20231218 Latest Revision: 20240522 Update Code: 20240523 PubMed Central ID: PMC10725274

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

Evaluation of the effect of erenumab on migraine-specific questionnaire in patients with chronic and episodic migraine.